CancerRop established CancerRop Cell on Wednesday, a subsidiary to develop cell therapy products, in joint funding with Gi-Innovation.
|Chairman of Myongji Hospital and president of CancerRop Lee Wang-jun|
With the launch of the subsidiary, CancerRop, which has been pursuing the development of customized immunotherapeutics through genetic analysis, has entered the cell therapy market.
As a joint-venture partner, CancerRop will take charge of integrated cell therapy for cancer targets, and Gi-Innovation will focus on immune regulatory cell therapy.
The new company will employ a double-CEO system with Lee Wang-jun, chairman of Myongji Hospital and president of CancerRop, and Professor Seo Joo-young of Ewha Woman’s University and co-CEO of Gi-innovation, as its new CEOs.
The first technology CancerRop Cell aims to develop is the Allogeneic ETC (Endogenous T Cell), an anticancer immune cell therapy.
CAR T cell therapy, currently the most popular anticancer drug, has a high response rate, but treats only hematologic cancer and has a complicated manufacturing process, which makes the treatment expensive.
On the other hand, the Allogeneic ETC technology can be applied to various types of solid cancer and also has a simplified manufacturing process, which enables it to maximize therapeutic effect by using a specific cancer antigen found in multiple carcinomas.
CancerRop Cell also plans to develop an inducible regulatory T Cell treatment that can suppress excessive immune responses in autoimmune diseases, inflammatory bowel disease, and metabolic diseases.
Gi-Innovation recently acquired a patent from a local university to use a chemokine receptor that promotes the migration of immune regulatory T cells derived from organs or tissues with abnormal immune responses and inflammation.
The company expects that the inducible regulatory T Cell treatment agents developed by using the technology can solve abnormal immune and inflammatory responses.
Researchers from the CancerRop, Myongji Hospital New Horizon Cancer Research Institute, and Gi-Innovation will conduct researches at the new subsidiary.
The company also plans to build a good manufacturing practice (GMP) facility, to accelerate the production of therapeutic drugs as soon as the transfer of patents and technology is completed, a company official said.
<© Korea Biomedical Review, All rights reserved.>